AR082501A1 - Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina - Google Patents

Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina

Info

Publication number
AR082501A1
AR082501A1 ARP110103029A ARP110103029A AR082501A1 AR 082501 A1 AR082501 A1 AR 082501A1 AR P110103029 A ARP110103029 A AR P110103029A AR P110103029 A ARP110103029 A AR P110103029A AR 082501 A1 AR082501 A1 AR 082501A1
Authority
AR
Argentina
Prior art keywords
piperazine
dimethyl
phenyl
therapeutic uses
phenylsulphanil
Prior art date
Application number
ARP110103029A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR082501A1 publication Critical patent/AR082501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Usos terapéuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil)]piperazina y sus sales farmacéuticamente aceptables. Uso del mismo en la preparación de un medicamento para el tratamiento a largo plazo de una enfermedad del SNC no asociada a un aumento de peso y también cuando el paciente padece una enfermedad adicional a la del SNC en la cual debería evitarse el aumento de peso tal como diabetes tipo II y cardiopatías coronarias.
ARP110103029A 2010-08-23 2011-08-19 Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina AR082501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201000739 2010-08-23

Publications (1)

Publication Number Publication Date
AR082501A1 true AR082501A1 (es) 2012-12-12

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103029A AR082501A1 (es) 2010-08-23 2011-08-19 Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina

Country Status (30)

Country Link
US (4) US20130184291A1 (es)
EP (1) EP2608789B1 (es)
JP (1) JP5902169B2 (es)
KR (1) KR101816953B1 (es)
CN (1) CN103068389A (es)
AP (1) AP3583A (es)
AR (1) AR082501A1 (es)
AU (1) AU2011295465B8 (es)
BR (2) BR112013002194A2 (es)
CA (1) CA2807062C (es)
CL (1) CL2013000492A1 (es)
CO (1) CO6680652A2 (es)
CY (1) CY1118886T1 (es)
DK (1) DK2608789T3 (es)
ES (1) ES2625142T3 (es)
HR (1) HRP20170608T1 (es)
HU (1) HUE034155T2 (es)
IL (1) IL224371A (es)
LT (1) LT2608789T (es)
ME (1) ME02674B (es)
MX (1) MX349724B (es)
PL (1) PL2608789T3 (es)
PT (1) PT2608789T (es)
RS (1) RS55851B1 (es)
RU (1) RU2564666C2 (es)
SG (1) SG187649A1 (es)
SI (1) SI2608789T1 (es)
TW (1) TW201212918A (es)
WO (1) WO2012025123A1 (es)
ZA (1) ZA201301385B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ATE138374T1 (de) * 1991-11-18 1996-06-15 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamide zur behandlung von krankheiten des zentralnervensystems
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP1322854A4 (en) 2000-10-02 2004-08-04 Rohr Inc APPARATUS, METHOD AND SYSTEM FOR REDUCING THE NOISE OF A GAS TURBINE
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
SI2044043T2 (sl) 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
JP5902169B2 (ja) 2016-04-13
US20210085674A1 (en) 2021-03-25
WO2012025123A1 (en) 2012-03-01
ES2625142T3 (es) 2017-07-18
JP2013536206A (ja) 2013-09-19
LT2608789T (lt) 2017-05-25
PT2608789T (pt) 2017-05-26
RS55851B1 (sr) 2017-08-31
MX2013001570A (es) 2013-03-21
ZA201301385B (en) 2014-04-30
SG187649A1 (en) 2013-03-28
US20220370439A1 (en) 2022-11-24
CN103068389A (zh) 2013-04-24
AP2013006768A0 (en) 2012-03-31
HUE034155T2 (en) 2018-01-29
BR112013002194A2 (pt) 2016-05-31
CA2807062C (en) 2018-07-31
ME02674B (me) 2017-06-20
CY1118886T1 (el) 2018-01-10
BR122020025600A2 (pt) 2021-01-05
SI2608789T1 (sl) 2017-06-30
DK2608789T3 (en) 2017-05-15
CO6680652A2 (es) 2013-05-31
AP3583A (en) 2016-02-09
CA2807062A1 (en) 2012-03-01
MX349724B (es) 2017-08-10
AU2011295465B8 (en) 2014-07-10
PL2608789T3 (pl) 2017-09-29
IL224371A (en) 2016-07-31
RU2013112890A (ru) 2014-09-27
KR101816953B1 (ko) 2018-01-09
HRP20170608T1 (hr) 2017-07-28
RU2564666C2 (ru) 2015-10-10
KR20130097162A (ko) 2013-09-02
AU2011295465B2 (en) 2014-06-19
TW201212918A (en) 2012-04-01
EP2608789B1 (en) 2017-04-12
AU2011295465A1 (en) 2013-02-07
US20130184291A1 (en) 2013-07-18
EP2608789A1 (en) 2013-07-03
CL2013000492A1 (es) 2013-06-07
US20190000836A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
DOP2016000158A (es) Análogos de cortistatina y síntesis y usos de los mismos.
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
AR082501A1 (es) Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP10010553A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
JP2017516842A5 (es)
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
CR11745A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatina debido a la administracion de dronedarona
AR078798A1 (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona
ES2546766T3 (es) Cenizas de las cascarillas de café una vez han sido tostadas y separadas del núcleo del café para uso como medicamento tópico
TN2010000465A1 (en) Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level
Reporter “Bringing-Light Tour”——Symbol of China-Pakistan Friendship

Legal Events

Date Code Title Description
FC Refusal